IKS to merge Turbo Health into US unit nine days after purchase
Key highlights
- IKS Inc. bought Turbo Health on November 10, 2026, five days after Turbo Health was incorporated.
- IKS disclosed board approval on November 19, 2026 to merge Turbo Health into IKS Inc.
- IKS Inc. reported FY 2025-26 revenue from operations of Rs 1,458.774 crore.
- The merger involves no cash consideration, no new shares and no change in IKS shareholding.
powered by IRIS

Inventurus Knowledge Solutions Limited said on November 19, 2026 that its US subsidiary, IKS Inc., approved the merger of Turbo Health Holdings, LLC into IKS Inc., nine days after buying Turbo Health on November 10, 2026. The merger would bring Turbo Health’s ambulatory revenue cycle management contracts into the main US entity without cash consideration or new shares.
Know Inventurus Knowledge Solutions inside out
Results, valuation, peers and who's buying, in one view.
Why is IKS merging Turbo Health into IKS Inc.?
IKS is merging Turbo Health into IKS Inc. to streamline its corporate structure after the November 10, 2026 acquisition. The filing says Turbo Health was incorporated on November 5, 2026 and holds contracts for ambulatory revenue cycle management, or RCM, services. IKS Inc. purchased Turbo Health and is the proposed transferee in the merger.
IKS said Turbo Health’s compact scale made maintaining a separate legal entity commercially unwarranted, while consolidation with the main US entity would enable operational streamlining. The November 19 filing does not quantify the acquired contracts’ value, customer count, employees, assets or liabilities. It lists Turbo Health’s turnover as not applicable because the entity was incorporated on November 5, 2026.
IKS received the information from its US subsidiary at 10:03 PM Indian Standard Time on November 19, 2026. IKS Inc.’s board approved the merger, which remains subject to applicable laws in the United States. The filing does not state an effective date, regulatory timetable or conditions beyond compliance with applicable US laws.
What business will IKS Inc. absorb from Turbo Health?
IKS Inc. will absorb Turbo Health’s ambulatory RCM contracts through the proposed merger while continuing to provide its care-enablement platform to healthcare providers. The filing describes IKS Inc.’s platform as comprising technology-enabled solutions for healthcare providers. Turbo Health is identified as operating in the ambulatory RCM segment.
The disclosure shows a difference in the entities’ reported scale. Turbo Health, incorporated on November 5, 2026, has no applicable turnover figure in the filing. By comparison, IKS Inc. reported revenue from operations of Rs 1,458.774 crore in fiscal year (FY) 2025-26 and total income of Rs 1,474.143 crore, including Rs 15.369 crore of other income.
The comparison is limited because IKS Inc.’s figures cover FY 2025-26, while Turbo Health was formed after that period on November 5, 2026. The filing therefore provides no pre-acquisition revenue comparison between Turbo Health and IKS Inc. It identifies Turbo Health’s disclosed role as holding ambulatory RCM contracts rather than reporting a turnover history.
Got a follow-up? Ask IRIS
Will IKS pay cash or issue shares for the merger?
IKS will not pay cash or issue new shares for the merger because Turbo Health is already wholly owned by IKS Inc. IKS Inc. purchased Turbo Health on November 10, 2026, and IKS Inc. is a wholly owned material subsidiary of IKS. The merger is therefore within the existing group ownership structure.
Turbo Health’s entire share capital will be cancelled once the merger becomes effective. The filing states there will be no cash consideration and no issuance of new shares, and it provides no share-exchange ratio. It also does not disclose a valuation for Turbo Health or financing connected with the merger.
IKS identifies the transaction as a related-party transaction because it combines a step-down wholly owned subsidiary with a wholly owned subsidiary. The company says the merger will be at arm’s length and subject to applicable US laws. The November 19 disclosure provides no merger-consideration amount because the transaction is an internal combination.
Does the Turbo Health merger change IKS shareholders’ ownership?
IKS shareholders’ ownership will remain unchanged because the merger is between two foreign subsidiaries of IKS. The company marks the shareholding impact as not applicable. No IKS shares will be issued or cancelled under the merger disclosed on November 19, 2026.
The ownership path in the filing is IKS as the listed parent, IKS Inc. as its wholly owned material US subsidiary, and Turbo Health as IKS Inc.’s wholly owned US subsidiary. When the merger becomes effective, Turbo Health’s separate share capital will be cancelled. The filing does not describe any change to the listed parent’s shareholder base.
The announced change is legal and operational rather than a change in control of IKS. Turbo Health holds ambulatory RCM contracts, while IKS Inc. provides a technology-enabled care-enablement platform for healthcare providers. The filing does not quantify any integration costs, savings or revenue impact from combining the two entities.
What remains unresolved in the IKS Turbo Health integration?
The merger’s effective date and legal timetable remain unresolved because IKS says the transaction is subject to applicable US laws. The board approval disclosed on November 19, 2026 permits the merger process to proceed, but the filing does not say that the merger has already become effective. No expected closing date, named authority or filing deadline is provided.
Commercial details also remain limited. IKS says Turbo Health holds ambulatory RCM contracts, but it does not disclose contract numbers, duration, counterparties or revenue contribution. It also does not state how the contracts could affect IKS Inc.’s FY 2025-26 revenue from operations of Rs 1,458.774 crore.
Conclusion
The November 19, 2026 disclosure shows IKS moving from its November 10 purchase of Turbo Health to a proposed internal merger with IKS Inc. The structure would place Turbo Health’s ambulatory RCM contracts in IKS Inc. without cash consideration, new shares or a change in IKS shareholding.
The next development to watch is confirmation that the merger has become effective under applicable US laws. IKS has not disclosed a closing timetable, contract-level revenue contribution, integration costs or expected savings, leaving those matters unresolved in the November 19 filing.


